# TABLE OF CONTENTS

Letter from the Chair and CEO ................................................................. 03
MRA by the Numbers .................................................................................. 04

## INVESTING IN THE NEW ERA

A New Era of Advancement ................................................................. 06
The Future of Immunotherapy & Cell-based Therapies ......................... 10
At the Forefront of Clinical Challenges: Tackling Melanoma Brain Metastases ................... 13
AI and Melanoma: Innovation for the Future ..................................... 15
RARE Registry: Providing Hope Through Innovation ...................... 18

## 2023 MRA AWARDS

Melanoma Research Alliance Grant Awards ........................................ 22
  Established Investigator Awardees .................................................. 22
  Young Investigator Awards ......................................................... 23
  Pilot Awards ............................................................................. 23
Dermatology Fellows Awards ............................................................ 24

2022 Tribute and Memorials ................................................................. 26
2022 Finances ..................................................................................... 28
2022 Donor Recognition ................................................................... 30

## THE PEOPLE OF MRA

Board of Directors .................................................................................. 35
MRA Team ............................................................................................. 36
Melanoma>Exchange Community Leaders ....................................... 36
MRA Scientific Advisory Panel 2022-2023 ....................................... 37
MRA Medical Advisory Panel 2022-2023 ......................................... 38
MRA Dermatology Council 2022-2023 ............................................. 40
Grant Review Committee 2022-2023 ............................................... 41
RARE Registry Oversight Committee 2022-2023 ............................ 43
MRA Leadership Council ................................................................. 43

---

As the largest non-profit global funder of melanoma research, MRA has dedicated over $150 million to date in support of the fight against melanoma.

Learn more at curemelanoma.org
The Melanoma Research Alliance is committed to ending suffering and death due to melanoma by collaborating with all stakeholders to accelerate research, advance cures, and prevent more melanomas.

MRA is a world leader in advancing transformational science that has caused paradigm shifts in what it means to be diagnosed with and treated for melanoma. We’ve directly invested over $150 million towards our lifesaving grants program — and leveraged an additional $415 million from outside partners — to advance our mission.

The innovative research we support isn’t just changing science — it’s giving patients more treatment options that translate to longer, fuller lives.

A person diagnosed with advanced melanoma today has access to 16 FDA-approved treatment options and hundreds of clinical trials that are enrolling patients to further improve our treatment arsenal. And while we still have many challenges ahead of us, the future of melanoma research — and the prognoses for patients facing this disease — have never been brighter.

This progress isn’t just benefiting patients with melanoma, it’s transforming the entire field of oncology. It’s a testament to the innovation and commitment of melanoma researchers that therapies that were conceived of, tested in, and first approved for melanoma are now being used to treat dozens of other cancers.

While we are proud of what we have achieved together, we know that there is still much work to be done. Throughout this report, you’ll find highlights of our most recent accomplishments, as well as stories of the researchers, clinicians, patients, and advocates who make this progress possible. You will also learn about our strategic priorities and goals for the future, as we continue to pursue our vision of a world where no one suffers or dies from melanoma.

We remain profoundly grateful for the patients who participate in research and for the support of our many advocates, donors, volunteers, partner organizations, government allies, and corporate colleagues who work with us to fund cutting-edge research, foster collaboration and innovation, and change the status quo surrounding melanoma prevention and sun safety.

Together, we can continue to accelerate the pace of discovery, translate research findings from the lab into the clinic, and improve the lives of millions of people affected by melanoma.

Sincerely,

DEBRA BLACK  
Chair and Co-Founder

MARC HURLBERT, PHD  
Chief Executive Officer
MRA By the Numbers

$151 million in grants
500+ funded investigators
444 research awards granted

$415+ million in leveraged and follow-on funding
29,328+ donors
20,000+ people have used MRA’s clinical trial navigator to find personalized clinical trial results in their community

MRA supported research... at 162 institutions and in 19 countries

230+ different agents for treatment of melanoma studied
722 corporate partners who’ve raised $68 million to support melanoma research

100% of all donations go directly to research—no admin, development, or other fees
INVESTING IN THE NEW ERA
INTRODUCTION

A New Era of Advancement

When MRA was launched 15 years ago, few could have imagined the catalytic effect it would have in both the melanoma and cancer research spaces. At that time, there was little by way of treatment options for patients with advanced melanoma, the field was all but stagnant, funding was difficult to come by, and most individuals with advanced disease died.

Despite the obvious obstacles, MRA boldly stated from day one its mission to cure melanoma. The organization knew that to make true innovations in the field, it must be willing to operate differently than organizations that came before it. It provides scientists and researchers the freedom and flexibility to take them where science, data, technology, and their intuition lead them. MRA fosters the next generation of melanoma researchers and clinicians with the tools and experiences they need to be the leaders of tomorrow. Similarly, MRA’s Annual Scientific Retreat promotes networking and new collaborations across institutions, borders, and specialty areas. The result? Breakthroughs in treatment, including the support of 16 new FDA approvals, improvements in quality of life and survivorship, and a whole new landscape with which patients, clinicians, researchers, advocates, and others can collaborate to further move the needle.
Over these 15 years, MRA has proudly invested more than $150 million directly into the world’s most promising science and research. This includes more than 440 grant awards yielding some of the best return on investment (ROI) in clinical research; nearly half-a-billion dollars in follow-on funding. MRA funding often represents an early-career investigator’s first major grant award, providing the resources they need to test their hypothesis and generate data, and ultimately yielding innovative discoveries providing the basis for future grant support for years to come. Similarly, MRA supports leading scientists from across the globe, giving them the funding and support they need to fully explore innovative ideas and paradigm shifting research. The result: measurable progress that makes a difference in the lives of patients every day.

“We know more about melanoma than we’ve ever known before—and in large part to the contributions of the MRA,” says Dr. Marc Hurlbert, Chief Executive Officer at MRA. “We know more about the biology of melanoma, treatment resistance, tumor mutations, how melanoma spreads and metastasizes, and the genetic difference between rare melanoma subtypes and cutaneous melanoma. Because of all the progress the field has made, we’re also able to identify the specific research gaps that exist.”

The juxtaposition between the research advancements and the research gaps are stark. Answering these questions, however, has become MRA’s North Star, directing the focus of what has become a new, bold, and ambitious plan. Efforts include MRA doubling its fundraising efforts — and capacity to fund innovative and lifesaving research — to an extraordinary $100 million dollars over the next 5 years. MRA is determined to actively move science forward, help patients most in need, and to scale as quickly as possible.

The vision includes four primary goals. These include:

1. **Developing new treatments for patients that don’t respond to existing therapies.** Although half of all patients with advanced melanoma benefit from existing treatments, the remaining half do not. “Even with the stories of triumph, success, and cure,” says Hurlbert, “we also have really devastating stories of lives cut too short — and it’s magnified because of the progress we’ve seen.” MRA is working hard to explore new treatments and novel immune therapies to address the gap where the current standard of care is not effective and to level the playing field for all patients. “We don’t want any patients to feel left behind,” says Hurlbert.

2. **Improving treatment options and outcomes for patients with brain metastases.** Melanoma has a high propensity to metastasize and spread to the brain and other central nervous system areas. Approximately 60% of patients with advanced melanoma develop brain metastases during the course of their disease.1 “We really need to understand why melanoma spreads to the brain and is able to go dormant, evading immune system detection, and what triggers melanomas out of that dormancy to initiate growth,” says Dr. Joan Levy, Chief Science Officer at MRA. Basically, why is the brain fertile soil for melanoma tumors to settle in and grow? MRA is working collaboratively across cancer types to better

---


“At MRA, we unite around research, the only way we will achieve a future beyond melanoma. But that research relies on us all. Everyone has a critical role to ending melanoma.”

Stephanie Kauffman, President and Chief Operating Officer at MRA
understand and develop treatments for brain metastases. We also have to ensure that when we find new treatments for brain metastases there will be clinical trials inclusive of these patients.

3. Translating new treatments for rare melanomas — including acral, mucosal, uveal, and pediatric melanoma. Patients with rare melanomas face unique challenges ranging from later diagnoses, poorer prognoses, and a lack of treatment options designed specifically to address the unique features of their tumors. MRA research investments of over $18 million have begun to advance the field’s understanding around the biology of these rare melanomas and their molecular genomics. To help answer additional critical questions, MRA has launched the RARE Registry (raremelanoma.org), a web-based, bidirectional, and interactive registry for patients with acral or mucosal melanoma. “Through the registry, patients with these rare melanoma subtypes can partner with researchers to accelerate research by helping the field better understand their unique patient journeys,” says Levy. “We’re also able to return de-identified data insights back to participants in real time. This allows them to access customized data snapshots to see how they fit into the entire cohort — something that can be really powerful for a rare cancer community. It’s exciting that participants can see research as it emerges as well as get tailored educational materials, clinical trial alerts, and webinars that they might be interested in,” says Levy. “The registry will be critical both in helping researchers get the data they need, but just as importantly helping them understand the patient’s journey as they experience it.”

4. Improving prevention, risk prediction, and diagnosis. Despite incredible progress in advancing new treatment options, melanoma continues to be the deadliest form of skin cancer with an estimated 100,000 new cases diagnosed each year in the United States alone. “There is an urgent need for new tools and new technologies to help a patient be empowered at home to check their own moles and for primary care doctors and nurse practitioners to say, ‘Aha, that is suspicious, let’s refer you to a dermatologist,’” says Hurlbert. “Dermatologists also need more tools, such as artificial intelligence and machine learning algorithms, to help them answer questions like, ‘Should I biopsy or not’ and then to assist pathologists to make definitive diagnoses.”

Just as MRA’s operating model has been unique, so too has its approach to partnerships. MRA helps bring together scientists, physicians, researchers, industry partners, government and regulatory officials, patients, advocates, philanthropists, and other nonprofit groups. This has been done through its Team Science Awards, nurturing collaborations across departments and institutions while also training a young investigator and through its Scientific Retreat where the best and brightest from across the world convene to share information and advance progress.
“I think that’s a real differentiator,” says Hurlbert, “we’re willing to partner with and collaborate with everyone. I think what we’ll see five years from now is that it won’t just be MRA working with other melanoma nonprofits, but we’ll also be working across cancer communities — from breast, to lung, and pan-cancer organizations like the American Cancer Society. “We’re also forging research partnerships with organizations beyond cancer,” says Levy. For example, research shows that some specific cells and proteins may play a role both in the neurodegeneration seen in Parkinson’s Disease and in the progression of melanoma. To explore this further, MRA partnered with the Michael J. Fox Foundation to co-fund two scientists. “It will take all of us working together to move the needle quickly.”

Activating this vision also requires new tools and strategies to engage the community. MRA is doing this through its online patient community, the Melanoma Exchange available at CureMelanoma.org/Community, its own digital communications channels, as well as a newly launched in-person salon series. Each salon is an intimate event that pulls in luminaries in the field to facilitate discussion about the future of skin health. “We are working with board members and other interested donors to open up their homes, or a place of their choosing, to create a dialogue with people who may not know about us but are interested in their skin health, melanoma, immunology, and where things are headed in terms of cancer research,” says Kauffman. To date, salons have been hosted in Los Angeles; Boston; Naples, Florida; Aspen; and New York.

MRA hopes that people leave with knowledge of all the interesting and groundbreaking work being conducted in cancer research. Moreover, investing in melanoma is very much an investment in cancer research broadly. Melanoma has been at the forefront of immunology, targeted treatments, and other innovations that have gone on to inform the way many other types of cancer are treated. “What happens first in melanoma often is then applied to other cancer types,” says Hurlbert. “It makes supporting melanoma research a very powerful way to advance oncology.”

MRA is also embracing science; working with patients to design the next generation of clinical trials; uncovering new answers — and questions — through its RARE Registry; and leading big data science projects with the Department of Veterans Affairs, the VA Hospital System, and Massachusetts General Hospital. Other MRA funded investigators are looking at cutting-edge technologies, including single cell analysis to study the tumor in context of its microenvironment including its neighboring cells, as well as projects in aging and how that impacts response to therapies.

Imagining what might be possible in the next five years, Hurlbert says, “It won’t be that MRA just funded it. It will be that we partnered and collaborated with everyone. We brought to bear tools to support patients, tools to improve diagnosis, and we’ll have supported the discovery of much-needed new treatment options. We’ll be the funder but also the partner and the collaborator in doing that research. We will be the leader moving the entire field forward. It’s not about redoubling the budget; it’s about recognizing the real sense of urgency that we feel a personal commitment to every day.”
The Future of Immunotherapy & Cell-based Therapies

“Melanoma research helped lead the way to a lot of paradigm shifts in cancer treatment,” says Dr. Antoni Ribas, Professor of Medicine, Surgery, and Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA).

Today, Ribas is a world-renowned physician-scientist, an elected fellow of the American Association for Cancer Research (AACR) Academy, the American Society of Clinical Investigation, and the National Academy of Medicine, among others. However, early in his career, Ribas was discouraged from pursuing tumor immunology.

“For a while, people were not keen on anyone who wanted to do research in tumor immunology,” he says. But Ribas was intrigued. He wanted to learn more about the biology of tumors and bring this knowledge to his patients. Tumor immunology studies the relationship between immune function and tumor cells, including the cellular and molecular mechanisms that affect how a tumor interacts with immune system cells, the tumor environment, and how the immune system can be harnessed as a treatment for cancer.

“Over the last 10 years, melanoma has been at the forefront of the development of immunotherapies and targeted therapies—informing research in many other cancers.”

Dr. Antoni Ribas

---

1Cancer Research Institute. “Antoni Ribas, MD, PhD.” Available at: www.cancerresearch.org/stories/scientists/antoni-ribas-md-phd
Reflecting on how the field has evolved, Ribas points to the number of therapies that were being studied just ten years ago in clinical trials that have now become standard of care for patients with melanoma. This has particularly been true for anti-PD-1 drugs, which Ribas knows firsthand.

That’s because ten years ago, he was the principal investigator of a large phase 1 trial studying the anti-PD-1 drug and checkpoint inhibitor pembrolizumab, which enables the immune system to better attack cancer. This work demonstrated how the immune system could lead to durable responses in patients and helped pave the way for melanoma treatment as we know it today.

“Another step forward has been the testing of anti-PD-1 antibodies before surgeries,” says Ribas. Currently anti-PD-1 immunotherapy has been approved to be given after surgery, what is called adjuvant therapy. However, what Ribas and others soon realized was that in doing so, they not only removed tumor tissue but also surrounding immune cells that could recognize the tumor. When immunotherapy was given following surgery, these potent anti-tumor immune cells would no longer be present to respond to anti-PD-1 antibodies.

To explore this area further, Ribas and his collaborator Dr. Sapna Patel (MD Anderson) conducted a study of patients who received three doses of immunotherapy first, underwent surgery, and then continued with immunotherapy. This approach, called neoadjuvant therapy, proved effective with a nearly 50% improvement of survival over adjuvant therapy.2 “This is another place where melanoma’s leading the way, because the paradigm should be the same for other cancers,” says Ribas. “We hope that patients with other cancers can benefit from immunotherapy before surgery.”

Ribas is exploring other innovative areas of treatment as well, including cell-based immunotherapy. Certain immune cells appear to recognize differences between melanoma and normal healthy cells. Ideally, these cells would be activated naturally by the body to attack cancerous cells. However, in situations where this does not work, scientists like Ribas are studying ways to take the immune system cells out of the body, grow them in a laboratory, and infuse them back into the patient. This is called cellular therapy for cancer and there are two main groups:

1. Immune cells purified from a surgically removed tumor or biopsy, called tumor-infiltrating lymphocytes or TILs, are expanded in the lab and reinfused back to the patient to elicit a stronger anti-tumor immune response.

2. Immune cells isolated from the patient’s blood are genetically modified to recognize and attack melanoma, and then infused back into the body. This gives the immune system cells a kind of “GPS” to find the melanoma and destroy it.

TIL therapy, first pioneered by Dr. Steven A. Rosenberg at the National Cancer Institute, is a labor intensive process and involves isolating specific immune cells from a surgically removed tumor and then giving nutrients to help them grow to very large quantities. This creates a proverbial army of immune cells that are then infused back into the patient with the goal of supercharging the immune response against and ultimately killing all cancerous cells. The field is closely watching several companies who are working to streamline this process into a safe, effective, and commercially available product.

Genetically modified immune cells (as mentioned in the second example above), have acquired new receptors to recognize and attack melanoma. “The key question is, do we

---

have receptors that redirect the immune system to melanoma in a safe way, avoiding the immune system attacking normal cells?” says Ribas. “This has not been the easiest thing to tackle, but progress is being made.”

Once the cell therapies are developed, patients still need to be conditioned with high doses of chemotherapy to deplete their existing immune systems. Once the immune system is wiped out, the new immune system — that has been carefully created for them in the lab — can be infused into the patient. This puts limitations on who can receive cell therapies because of the toll it takes on the body.

“Cell therapies have become the standard of care in patients with lymphomas, leukemias, and multiple myeloma,” says Ribas. “We know that the same principles could work in melanoma, because of TIL therapy, but more work is still needed to better target those immune system cells.”

Although there is still more work to be done, it’s incredible to see just how far the field has come. A big contributor of this work has been MRA. “Since its founding, MRA has been the largest non-profit funder of melanoma research,” says Ribas.

“The grants chosen for funding by MRA are reviewed by a panel of experts that include the best in the field. MRA’s early stage grants enable researchers to venture into new fields and are very important to opening up new areas of research,” he says.

“As scientists we try to understand the problems that limit treatments and then we innovate from there, hoping that what we discover can have a beneficial impact on the patients we serve,” says Ribas. “This approach is what leads to advances both in our scientific understanding but also in improved patient outcomes.”

And it’s working.

“If we look back 10 years ago, less than 1 in 20 patients had a chance to live long-term,” says Ribas. “Now, close to half of the patients with advanced melanoma are living years beyond their diagnosis, and probably many of them have in fact been cured. That’s why we as scientists continue to do what we do. This is the power of research — and I’m proud to be part of it.”
Not many people can pinpoint the exact moment their lives changed forever, but for Dr. Inna Smalley, Assistant Member at Moffitt Cancer Center, that moment came after a health scare when she was young. “I had a growing tumor that affected me,” she says. “It was a lymphatic malformation. I went from resection and relapse for years without anyone knowing what to do, what it was, or how to treat it.”

But hope finally came. “One day I met a clinician who said, ‘I know what this is, and I know of a clinical trial.”

The clinical trial was a success in more ways than one. Smalley responded well to treatment — and she got her first glimpse into medical research. “I thought, ‘Wow! There are people doing research and it affects how things are managed clinically,” says Smalley. “That’s when I knew I was interested in this work.”

Today, Smalley's research — supported in part by an MRA Young Investigator Award co-funded by the Tara Miller Melanoma Foundation — is focused on one of the biggest challenges facing patients with melanoma today: treating those who have brain metastases. This is an urgent area of unmet patient need, because despite dramatic advancements in melanoma research overall, the understanding and treatment of brain metastases has lagged behind.
Brain metastases represent one of the most difficult-to-treat complications of melanoma and are a significant cause of patient morbidity and mortality.

Today, nearly 40% of patients with metastatic melanoma have brain metastases at diagnosis. This figure increases to 75% of patients at autopsy.

While currently approved therapies do work in the brain in some patients, they are far less effective at treating tumors there than in other parts of the body.

Among solid tumors, rates of brain metastases are higher in melanoma patients than many other cancers.

"Historically the brain has been an area that’s difficult to study," says Smalley. "We haven’t had a lot of access to brain metastatic tumors to even figure out what’s going on. We really don’t know why cells respond differently to therapy in the brain than they do at other sites."

What Smalley’s research hopes to do is better understand how melanoma metabolism in the brain affects the pro-tumor, immune-suppressive functions of cells called astrocytes. Astrocytes play an incredibly important role of protecting brain tissue, supporting homeostasis of the central nervous system, and helping repair damage.

In many ways, astrocytes are like our body’s police, emergency medical technicians (EMTs), and traffic safety unit all in one: They help keep orderly function, support healthy blood flow, and can protect and repair. However, when tumors spread to the brain, they adapt to their new environment by changing their metabolism which can affect the function of normal cells surrounding them such as astrocytes. As a result, astrocytes don’t just ignore tumor cells, they treat them like never-healing wounds, ultimately promoting tumor survival in an otherwise harsh environment. Smalley is studying the metabolic programs in melanoma cells that have infiltrated the brain to identify vulnerabilities within the tumor-astrocyte interaction. Doing so could lead to the identification of new drugs that can increase the effectiveness of existing treatments, and ultimately weaken the tumor’s hold on the brain.

Smalley’s award is co-funded by the Tara Miller Melanoma Foundation, which was founded by Tara Miller in 2014 following her diagnosis with melanoma. While Tara tragically passed away later that year at just 29 years old, her legacy continues. Over the last decade, the Tara Miller Melanoma Foundation has raised over $7.5 million to support melanoma research at both University of Pennsylvania and in partnership with MRA.

“I’m truly honored to have received the award from MRA and the Tara Miller Melanoma Foundation,” says Smalley. “Tara’s faith in research and vision of rendering cancer powerless by advancing science resonates with me.”

Smalley says grant awards like the one she received are both humbling and incredibly impactful. “The funding environment can be brutal, especially for young investigators because we don’t yet have a history of successful funding. These grants are like a bridge to begin our research and secure future funding. They allow us to take risks with good ideas, build up evidence, encourage more people to study it, and make an impact clinically.”

Smalley says that the intent of her research is to be very translational. To do this, she tries to be as tuned into what’s happening clinically as possible, so she regularly participates in tumor boards and discussions with clinicians. When possible, she even shadows clinicians to better understand patient perspectives and what is important to them. “I want to address questions that are directly relevant to patient care in the clinic,” says Smalley.

And she is. Although it’s still early in the research project, preliminary data suggests that Smalley’s hypothesis may be right: Tumor cells affect astrocyte function; and astrocytes may be improving tumor cells’ ability to grow and survive in the brain microenvironment.

“This work is possible because of advocacy and patient involvement. Without having access to tissues to study and samples to study, we wouldn’t be able to do any of this. I want to tell patients and their families how valuable their contribution has been to our research in the field,” says Smalley. “I want them to know that their willingness to participate makes a huge difference in advancing scientific knowledge and we are very grateful.”
“Artificial intelligence (AI) is going to transform how we diagnose, treat, and eventually overcome melanoma,” says Dr. Veronica Rotemberg, Director, Dermatology Imaging Informatics Program at Memorial Sloan Kettering Cancer Center.

Rotemberg believes in the incredible role that AI can play in the detection and treatment of melanoma. Through the International Skin Imaging Collaboration (ISIC), there are more than 75,000 publicly available images of different skin conditions. In addition, ISIC has hosted five yearly challenges related to melanoma—with AI programs in the competition consistently demonstrating better and better performance at diagnosing the disease. It’s an incredible collaboration that has yielded millions of image downloads, advanced published research, and had an extensive ripple effect on the reach and impact of melanoma research.

Rotemberg sees AI playing a number of different roles in melanoma, including:

- Reducing the number of benign biopsies,
- Improving prognosis and treatment selection,
- Identifying more melanomas, and
- Helping to address research voids.

“AI AND MELANOMA

Innovation for the Future

“When you want to identify something that could be a game changer, [AI] is the way to go.”

Dr. Veronica Rotemberg
While AI has earned considerable media attention in recent years based on reports of its ability to outperform dermatologists in head-to-head competitions, these competitions have typically been based solely on images of lesions with little additional context. However, like many things the devil is often in the details. In clinical practice, dermatologists have the benefit of seeing patients — and their skin — in real life and up close. Dermatologists also have access to additional information, including patient and family medical history, that can help refine decision making.

Rotemberg’s research, supported by a Michael and Jacqueline Ferro Family Foundation-MRA Young Investigator Award, is working to improve AI by determining what contextual information is most helpful to improve its performance in specific situations.

“There are certain types of information that might help the models perform better in specific situations, for instance in certain anatomic sites or with certain types of imaging features,” says Rotemberg. “It really depends on the distribution of data that the models are trained on. Ours was one of the first quantitative evaluations of how model performance might change with different [contextual] inputs.”

As a leader in this field, Rotemberg is also assessing and validating existing algorithms, which is a critical area of research, especially as AI becomes more integrated into doctors’ decision making in the clinic. For example, current models were not sufficiently trained using images of diverse skin tones and as a result they aren’t as accurate when applied to people with darker skin.

Rotemberg’s work will help change this by ensuring that models are assessed for bias and that the underlying data is appropriately labeled, making it easier to understand potential benefits and harms of a particular model. This also streamlines the benchmarking and validation process that will be required for wider adoption.

“At some point in the future, AI-enhanced tools for melanoma detection will end up in the clinic,” says Rotemberg. “As we usher in this new and exciting era, we need to do the work now to ensure these technologies are actually providing the benefit we intend.”

According to Rotemberg, there are more than 500 AI algorithms approved by the FDA today; but none in melanoma. She wants to change this by helping to identify what outcomes are most important to patients and then ensure that there are appropriately validated and benchmarked models that result in marked improvements in those outcomes.

Also helping advance the field is funding, like that from the MRA and the Ferro Foundation. “I think the science was really advanced by the award,” says Rotemberg. “We’ve received numerous subsequent awards building off that initial work and our findings have been published in several journal articles. The collaborative opportunities we’ve identified by being part of MRA’s network have been incredible. I never want MRA’s impact to just be measured by the papers and grants that came directly from a project, because there’s so much more that comes out of being connected with them on a personal and professional level.”

Although the AI field is advancing quickly, Rotemberg thinks more innovations are needed in the following areas:

- Data curation, acquisition, and quality control,
- Standards development, and
- Identifying the right patient outcomes.

“AI research is expensive but when you want to identify something that could be a game changer, this is the way to go,” says Rotemberg.

A DEEPER LOOK

Dr. Kamran Avanaki, Associate Professor in the Biomedical Engineering and Dermatology Departments at the University of Illinois Chicago agrees. “I think AI in dermatology is a must. It’s not a choice anymore because it really is the result of experts’ accumulated experiences and there is power in that.”
Like Rotemberg, Avanaki is trying to harness AI’s abilities to advance melanoma research, improve diagnosis, and determine when or even whether a biopsy is actually needed.

Avanaki became interested in melanoma research during his PhD training, when he realized that non-invasive optical imaging could be used to explore and understand skin health with great accuracy. Avanaki also saw the incredible challenge faced by dermatologists in differentiating between melanoma and benign moles using the naked eye. Studies have shown that the ratio of benign lesions to melanoma biopsies can range from around 10 to 1 up to 50 to 1 depending on the experience of the dermatologist and patient medical record. This means that for every melanoma found, there may be anywhere from 10 to 50 or more benign lesions that were biopsied.

Surgical biopsy isn’t a no-risk procedure for patients. It can result in pain, anxiety, and scarring — not to mention additional healthcare costs. Moreover, identifying malignant lesions in areas of the skin with many pigmented spots, such in the case of a person with many freckles, is difficult with visual inspection alone. “To overcome these challenges, we have developed a computational method that, using a sophisticated algorithm, analyzes the Optical Coherence Tomography (OCT) images of skin and differentiates melanomas from benign nevi,” says Avanaki.

OCT is a non-invasive imaging technique that uses low energy safe infrared light to capture high-resolution, cross-sectional images of body tissues in real-time at a microscopic level. Compared to photo-based AI models, OCT is much less sensitive to patient characteristics such as age, skin color, and gender which would eliminate lots of dataset diversity problems.

Currently, Avanaki’s OCT-based algorithm can differentiate melanoma from benign nevi with 99% accuracy, demonstrating a significant improvement in melanoma detection over other diagnostic technologies.

“We’re now working to further optimize the algorithm to improve accuracy, consistency, and its implementation in the OCT software so we can then launch a preliminary clinical trial,” explains Avanaki.

Avanaki’s hope is that his technology can assist clinicians in accurately diagnosing melanoma while reducing the need for surgical biopsies.

To use this technology, a patient sits down, and the clinician places a probe — resembling what is used for an ultrasound — on the suspected lesion. The system generates a 3D image and Avanaki’s algorithm examines the generated image to determine the probability of the lesion being melanoma (or not) and provides additional technical information that can help inform the clinician’s decision making.

In the near future, dermatologists could use this tool as opposed to performing a biopsy and then waiting for results. “When dealing with patients,” says Avanaki, “I see the huge hope in their eyes when we tell them that we’re using this methodology and we don’t need to do a [traditional] biopsy.”

Avanaki says that the MRA and the Ferro Foundation funding used to support the development of this algorithm has been incredible in helping refine and validate the work as well as for training the next generation of AI researchers. In the future, Avanaki hopes to make this technology more available to dermatologists, develop a related process to help support clinicians in staging a melanoma lesion, and he wants to develop a low-cost, miniaturized version that patients can use at home on any suspected lesions. The latter would be a gamechanger for people with many moles, a history of melanoma, or those who live in low-resource areas or have limited dermatology access.

As Rotemberg and Avanaki have shown, when it comes to AI’s application in melanoma and clinical cancer research, the future is bright and the possibilities are within reach.
Each year approximately 5,000 patients are diagnosed with acral or mucosal melanoma. These rare melanoma subtypes arise in non-sun exposed areas and are not believed to be caused by UV damage. Due to the relative obscurity of these rare subtypes, patients face mounting challenges ranging from late diagnoses, lack of support, limited — and often dated — access to information, and overall poorer prognoses. Treatment options are also more limited and less effective for these rare melanoma subtypes than for the more common cutaneous melanoma that forms on sun-exposed skin.

To address this, MRA launched the RARE Registry — a first-of-its-kind, direct-to-patient registry focused on acral and mucosal melanoma — in 2022. The registry:

- Collects data directly from patients with acral or mucosal melanoma using a series of surveys available online.
- Returns real-time de-identified information collected from participants in the form of ‘Insights’, provides educational opportunities that highlight emerging science and ways to connect with researchers and other advocates, and notifications about pertinent clinical trials.

The RARE Registry is an example of MRA’s unique ability to listen and respond to community needs while also addressing research gaps.

---

1Melanoma Research Alliance (MRA). RARE Registry. Available at: www.curemelanoma.org/research/rare-registry
• Provides researchers and clinicians with an unprecedented look into the disease journey of patients with these rare melanoma subtypes, giving them the information they need to develop more effective treatment strategies.

• Includes an Oversight Committee comprised of patients, caregivers, and a multidisciplinary group of medical advisors to help further guide the registry over time.

The RARE Registry is an example of MRA’s unique ability to listen and respond to community needs while also addressing research gaps. “MRA answered the call on every level,” says patient advocate and registry advisor Julie Dewey. “They were the only group who could do it all. They could find the funding to support it; they had the team in place to create the surveys needed to collect the most pertinent information; and they were familiar with other cancer registries. They also had the ambition and the compassion to make it happen with the patient community. Finally, they understood the immediate need — lives were on the line.”

The idea for the registry began years earlier in a Facebook support group called the Mucosal Melanoma Warriors, where a few hundred patients and family advocates shared information about their healthcare journeys as well as providing one another with much-needed support. Through this group, Dewey met Dr. Alfonso Waller. The two bonded, sharing information about their spouses who were diagnosed with mucosal melanoma: Dewey’s husband Chris was diagnosed at age 48 and Waller’s wife Lisa was diagnosed at age 39, 6 weeks after their second daughter was born. Everywhere they looked, the information available about the disease was based on a small sample of patients and did not line up with the journeys they were on.

As they explored this further, they discovered that many individuals in the Facebook group had experienced delays in getting a correct diagnosis. Moreover, even when properly diagnosed, there was no clear standard treatment protocol; and trends seemed impossible to identify across demographics, age, gender, and area of diagnosis — especially when any one medical center saw only a handful of patients with rare melanomas each year. “The more Alfonso and I talked, the more we wanted to find a way to bring patients together to accelerate research alongside the doctors and researchers. We wanted tumor DNA to be studied. And we wanted all of this in one place,” says Dewey.

As they spoke to their extended network, the idea continued to blossom. Together, they dreamed of a community where patients and caregivers could help accelerate research by providing information and by helping set research priorities; a place where they could ask questions, seek support, and get updates on the latest advances; and a place where rare melanomas would always be front and center.

“We wanted answers for our community, and we wanted our community to be part of finding those answers,” says Dewey.

Thanks to a mutual friend, Waller was able to get in touch with MRA’s CEO Dr. Marc Hurlbert and he pitched just that. “I suggested we bring together a community of patients, caregivers, and advocates who’ve been impacted by rare melanomas to create a registry,” says Waller. “Marc was very excited, and he told me about his experience with a similar-type of registry he led in the breast cancer space.”

As the MRA team looked further into direct-to-patient registries, it became clear that patients with mucosal melanoma weren’t the only ones who could benefit from such a project. While patients with uveal melanoma — which affects the eye — had several registries open to them, those with acral melanoma had no such options.

The MRA team quickly set up conversations with advocates from the acral melanoma community. Call after call, similar frustrations about delays in diagnosis, lack of standard treatment plans, and feelings of isolation kept coming up.
“The challenges experienced by these two communities — while distinct on the surface — are quite similar,” says Dr. Hurlbert. “More important than similar challenges, it was clear that advocates from both communities were eager to work together to change this status quo. That’s when we knew that this project needed to move forward.”

The RARE Registry was not only an idea by advocates, caregivers, and patients — they have quite literally been at the helm of designing it at every juncture, from its name, branding, web and mobile capabilities, survey questions, and even the request for a longitudinal study and tumor data.

The registry is creating a different journey for the betterment of patients with acral and mucosal melanoma. What was a once terrifying diagnosis riddled with outdated statistics and fear is now met with accurate information, community, and hope. It is nothing short of empowering. For example, the RARE Registry is focused on better understanding the quality of life throughout the treatment journey, from diagnosis to survivorship — something often overlooked by researchers but critical to patients.

It also allows participants to see how they fit into the larger picture by comparing their responses to others who have also answered specific survey questions. It’s a lifeline during an otherwise scary and far too often isolating journey.

As she reflects on this registry journey, Dewey says, “Chris’ life was not in vain. When he was diagnosed, he already had Stage 4 disease. We knew this registry wouldn’t come in time to benefit him but, rather, for future patients diagnosed with mucosal melanoma. It feels remarkable to have created this registry. In that way, Chris was a pioneer. He had a purpose in his life, and I strongly believe the registry was it.”

Above, Julie Dewey holds photo of her husband Chris. Below, Dr. Alfonso Waller, Alfonso’s late wife Lisa, and their two daughters.
2023 MRA AWARDS

A searchable database of all MRA grants is available at CureMelanoma.org/Grants
ESTABLISHED INVESTIGATOR AWARDEES

Memory T cell responses in primary melanoma
MRA Established Investigator Award, collaboratively funded by University of Michigan
Christina Angeles MD, The University of Michigan

Armoring CD8+ T cells against energetic deficiency in melanoma
Leveraged Finance Fights Melanoma — MRA Established Investigator Award
Timothy Bullock PhD, University of Virginia

Therapeutic targeting of Hdm2/HdmX E3 ligase in melanoma
MRA Established Investigator Award
Julio Camarero PhD, University of Southern California

Genetic mechanisms early melanoma progression
Anna-Maria and Stephen Kellen Foundation — MRA Established Investigator Award
Adam Dupuy PhD, The University of Iowa

Mechanisms underlying the oncogenic role of ORAI2 in melanoma
MRA Established Investigator Award
Stefan Feske MD, New York University Grossman School of Medicine

Dissecting the mechanisms of melanoma cell adaptation to the brain
MRA Established Investigator Award
Eva Hernando PhD, New York University Grossman School of Medicine

Precision, plasma-only, melanoma ctDNA residual disease monitoring
Ellen and Gary Davis — MRA Established Investigator Award
Dan Landau MD, PhD, Weill Medical College of Cornell University

Sustaining metabolic fitness of antitumor CD8+ T cells
MRA Established Investigator Award
Bin Zhang MD, PhD, Northwestern University
YOUNG INVESTIGATOR AWARDS

Harnessing the immunomodulatory effects of NK cells in melanoma
Bristol Myers Squibb — MRA Young Investigator Award
Kevin Barry PhD, Fred Hutchinson Cancer Center

Dissecting the dynamic immune ecosystem during melanoma evolution
Leveraged Finance Fights Melanoma — MRA Young Investigator Award
Diego Chowell PhD, Icahn School of Medicine at Mount Sinai

Vaccine-tunable TME-restricted CAR T therapy for long-term melanoma control
Bristol Myers Squibb — MRA Young Investigator Award
Leyuan Ma PhD, The Children’s Hospital of Philadelphia

Dissecting melanoma brain metastasis and response to immunotherapy
MRA Young Investigator Award
Eva Perez-Guijarro PhD, Universidad Autónoma de Madrid

Catabolic plasticity in acral melanoma metastases and drug tolerance
The Black Family — MRA Young Investigator Award
Vito Rebecca PhD, Johns Hopkins University

Bioengineering approaches for advancing targeted-immunotherapy in melanoma
MRA Young Investigator Award
Tanmoy Saha PhD, Brigham and Women’s Hospital

Multi-modal machine learning for early-stage melanoma recurrence prediction
L’Oreal Dermatological Beauty — MRA Young Investigator Award
Yevgeniy Semenov MD, Massachusetts General Hospital

Image-based three-dimensional radiation dosimetry for Ac-225-MTI-201
ASTRO — MRA Young Investigator Award
Chris Tichacek PhD, H. Lee Moffitt Cancer Center & Research Institute

Resolving the spatial clonal architecture of acral lentiginous melanoma
L’Oreal Dermatological Beauty — MRA Young Investigator Award
Meng Wang PhD, The University of California, San Francisco

Monitoring early response to immunotherapy with ultrasensitive plasma WGS
The Black Family — MRA Young Investigator Award
Adam Widman MD, Sloan Kettering Institute for Cancer Research

Tumor immune evasion through STING-mediated T cell death in melanoma
MRA Young Investigator Award
Jianjun Wu PhD, Cleveland Clinic Foundation

PILOT AWARDS

The CoREST repressor complex as a mediator of RNA splicing and tumor growth
Leveraged Finance Fights Melanoma — MRA Pilot Award
Rhoda Alani MD, Boston University

Epigenetic determinants of melanoma progression and immunotherapy response
The Denise and Michael Kellen Foundation — MRA Pilot Award
Alfonso Bellacosa MD, PhD, The Research Institute of Fox Chase Cancer Center

Identifying genetic sex biasing factors in melanoma progression
The Denise and Michael Kellen Foundation — MRA Pilot Award
Nora Engel PhD, Temple University
Targeting ASAP1-induced transcription factors in metastatic uveal melanoma
ACIS — MRA Pilot Award in Metastatic Uveal Melanoma
Shannon Odelberg PhD, The University of Utah

A drug-binding assay platform to optimize therapies for RAS-mut melanomas
MRA Pilot Award
Poulikos Poulikakos PhD, Icahn School of Medicine at Mount Sinai

Dermatology Fellows Awards

Two Homeodomain-Dependent Gene Regulatory Networks Rewiring Melanoma Heterogeneity and Enhancing Tumorigenesis
MRA Dermatology Fellows Award
Pietro Berico PhD, New York University Grossman School of Medicine

The Role of APOE Isoforms in the Hereditary Basis of Rare Melanomas
MRA Dermatology Fellows Award
Neil Neumann MD, PhD, The Rockefeller University

Epigenetics and Acral Melanoma Prognostic Model for Skin of Color Patients
MRA Dermatology Fellows Award
Simon F. Roy MD, Yale University

Micronuclear Rupture and DNA Damage in Primary Cutaneous Melanoma Prognosis
MRA Dermatology Fellows Award
Xiao Zhang PhD, The University of California, Los Angeles
In 2022, gifts were made in tribute to the following individuals.

**Memorial Gifts**
- Diane Abis
- Bambi Adams
- John Adams, Jr.
- Barbara Nudell Aletkin
- Joan Anania
- Susan Andersen
- Frederick Arnold III
- Ruth Aylor
- Phillip Babin
- Leticia Quintana Barron
- Michael Barry
- James Bedell
- John Beer
- Christopher Bernardo
- Paulette Bilke
- William David Boden
- Christina Bourke
- Richard Bretz, Jr.
- Charles Brooks
- Thomas Brown
- Gary Bruington
- Brady Button
- Ed Calamese
- Walter Cehanowicz
- Philip “Chip” Chiappia
- Joanne Cioppi
- Rusty Cline
- Donald “Dan” Cowen
- Jeanne Danis
- Gary Daum
- Hollie Jo Dean
- Corinne Derrig-Rivera
- Michael Dilworth
- Leslie Dixon
- Alison Dwelley
- Sharon Elczyzyn
- Laura Elken
- James D. Evans
- Gerald W. Fagert II
- Danny Federici
- Joseph Feehan
- Janet Fiebert
- India Field
- Tony Finnerty
- Christian Fisher
- Will Flewelling
- Clayton Ford
- Daniel Forte
- John Fredlund
- Jann Freehling
- Paul French
- Pearl Friends
- Chelsea Frueh
- Ronnie Gallagher
- Wayland Gardner
- Frederick Gessler
- Bill Gorden
- Lynne Greenberg
- Derek Haehnel
- Gary Halverson
- Stuart Handelsman
- Christine Cowan Hanson
- James “Jimmy” Harp
- James “Dick” Harper
- Joel “Gus” Harris
- Anna Hennessy
- Kathy Herbert
- Jackie Herchl
- Patricia Holtsclaw
- Benjamin Horton
- Merlin Howard
- Amy Horwath
- Jeanne Hotchkiss
- Judith Howard
- David Huber
- Daniel Hudak
- Douglas Huff
- Jason Hurt
- Tom Hutchings
- Sue Jacobs
- Karen Joyce
- Lynn Kadela
- Bruce Kahler
- Wendy Kane
- David Benjamin Kantor
- Kari Thompson Kelemen
- Tara Kelly
- Ralph Kendall
- Gordon King
- Melissa King
- Bob Klein
- Robert Klumpp
- Michael Konigsberg
- John Krebs
- Leslie Kuhl
- Lisa Lais
- Steven Lam
- Paul Larson
- Alfredo Solorzano Llamas
- Jeffrey Lobelson
- John Lohl
- Vern Lysford
- Nancy Malis
- Gail McKnigh
- Mike McDonald
- Michael McGuire
- David Meisner
- David Merlene, Sr.
- Naomi Miller
- Jessie Minton
- Stephen Mitchell
- John Mixen
- Mark Mobley
- James Montgomery
- Jim Moore
- Rodney Moore
- Boots Morehead
- Zackery Morgenson
- Dennis Mosebar
- Winfred Mullen
- Janice Murphy
- Judy Nanni
- Thomas Nyquist
- Edward O’Hara
- Paul Ostrowski
- Frank S. Owens
- Angelina Patierno
- Tim Patrick
- Martha Pfershy
- Julie Pietrantoni
- Kurtis Poorman
- Scott Raferty
- Eugene Reilly
- Joshua Rogers
- Leyla Rojas
- Mark Rolfs
- Edna Ruediger
- Mark Russell
- Mary Ellen Russert
- Joan Salyer
- Mark Samitt
- Edward Sandall
- Kenneth Scavo
- Jeffrey Schacter
- Timothy Schiefelbein
- Howard James Schlegel
- Alfred Seidel
- Arka Shanks
- Francine Shaw
- Mary Shobe
- Jennifer and Cecilia Rose Shushereba
- Anthony Sitter
- Charles T. Skulsky
- Dean Smith
Heidi Smith
Kenneth Smith
Bob Sneed
Jon Snemyr
Joel Solomon
Katie Stavola
Rita Steiner
Catherine Sugarbaker
Eric Sweet
Kristin Taccogna
Rosemary Meehan Tator
John Taylor
Donna Teel
Lucille Theis
Jennifer Thomas
Dino Tinti
Donna Turner
Mary Ann Ungerson
Cassandra VanVeghten
James A. Vick, Jr.
John P. Vidal
Joseph Vidulich
Richard Wagaman
Rich Walsh
Richard Warren
Grace Wenzel
Carol Westemeier
Marc Widoff
Allen Williams
Kay Wilson
Tracy Windrum
Sally Wolfish

**Tribute Gifts**

Lacey Adams
Amanda and Jon Alagem
Sandi Alcantar
Camille Atkins
Cody Barnett
Brandon Barnica
Ron Beaufort
Ben and Charlotte Black
Debra Black
Karen Bradbury
Corey Brake
Lindsey Branston
Joe Brooks
Trena Brown
Moshe Bunzel
Eddie Calamese
Julie Callahan
Tracy Callahan
Jean Carroll
Bonnie Chan
Marina Chan
Darcey Chisholm
Marilyn Clayton
Gayle Cohen
Anne and Lynn Conley
Richard Copsey
Aaron Cummins
Jon Davidson
John and Maureen Drumm
Sandy and Tom Elken
John Elson
Johnny Evans
William Evans
Jason Federici
George Ferris
Garland Fitzgerald
Jenny Fowlie
Stanley Franklin
Nelson Freed
Candice Gardner
David Glass
Naomi Godfrey
Jamie Goldfarb
Elianna Goldstein
Jay Harris
Jake Heaser
Carrie Hendricks
Jordan Henshaw
Connor Holcomb
Jonathan Holcomb
Dana Huennekens
Marc Huennekens
John Janiak
John Kessler
Patti King
Robbie King
Alexandra Kohut
Leah Koskinen
Jake Kreig
Mark Langley
Gerry Lefever
Dan J. Levine
George Lewis
Sharon Lewis
Lara Madden
Jacquelyn Malis
Brian Malyon
David Marx
Ryan Mason
Gary Matz
Pamela Mayer
Jason and Megan McFadden
Sharon Mexal
Melanie Montgomery
Kira Muller
Elmer Nelson
Suzanne Osborne
Brandon Owen
James Perkins
Lauren Platt
Barbara Premisler
Camille Price
Derrick Queen
Aimee Rau
Georgina Raygada
Doane Rising
Melanie Robert
Peggy Robinson
Mary Jo Rogers
Kimberly Tishler Rosen
Jeffrey Rowbottom
Craig Schuh
Ian Schuman
Ben Schmidt
Barbara Shatkin
Misti Shipp
James Skelton
Maya Skubatch
Bill Smith
Robert Sneed
Kathleen Valentine
Robert Villarreal
Eileen Walther
Katelyn Wenthe
Brittany Whitfield
John Williamson
Pamela Willis
## Statement of Financial Position

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>TOTAL 2022</th>
<th>TOTAL 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$10,912,733</td>
<td>$12,982,423</td>
</tr>
<tr>
<td>Investments</td>
<td>$10,877,034</td>
<td>$11,630,333</td>
</tr>
<tr>
<td>Contributions Receivable (Net)</td>
<td>$5,454,387</td>
<td>$7,549,216</td>
</tr>
<tr>
<td>Prepaid Expenses and Other Assets</td>
<td>$89,192</td>
<td>$105,490</td>
</tr>
<tr>
<td><strong>TOTAL ASSETS</strong></td>
<td><strong>$27,333,346</strong></td>
<td><strong>$32,267,462</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES</th>
<th>TOTAL 2022</th>
<th>TOTAL 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable</td>
<td>$133,430</td>
<td>$152,043</td>
</tr>
<tr>
<td>Grants Payable (Net)</td>
<td>$13,069,601</td>
<td>$12,382,532</td>
</tr>
<tr>
<td>Deferred Revenue</td>
<td>$277,500</td>
<td>$609,500</td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES</strong></td>
<td><strong>$13,480,531</strong></td>
<td><strong>$13,144,075</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>NET ASSETS</th>
<th>TOTAL 2022</th>
<th>TOTAL 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unrestricted</td>
<td>$12,027,815</td>
<td>$16,300,897</td>
</tr>
<tr>
<td>Temporarily Restricted</td>
<td>$1,825,000</td>
<td>$2,822,490</td>
</tr>
<tr>
<td><strong>TOTAL NET ASSETS</strong></td>
<td><strong>$13,852,815</strong></td>
<td><strong>$19,123,387</strong></td>
</tr>
<tr>
<td><strong>TOTAL LIABILITIES &amp; NET ASSETS</strong></td>
<td><strong>$27,333,346</strong></td>
<td><strong>$32,267,462</strong></td>
</tr>
</tbody>
</table>

Financial presentation based on MRA’s 2021 externally audited financials. Full audit and IRS 990 are available online at [CureMelanoma.org/Financials](http://CureMelanoma.org/Financials)
Statement of Activities

**REVENUE**

<table>
<thead>
<tr>
<th>Description</th>
<th>TOTAL 2022</th>
<th>TOTAL 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions (Collectible Net)</td>
<td>$7,877,755</td>
<td>$4,786,386</td>
</tr>
<tr>
<td>Special Events (Net)</td>
<td>$2,651,407</td>
<td>$2,046,963</td>
</tr>
<tr>
<td>Sponsorship</td>
<td>$744,500</td>
<td>$459,555</td>
</tr>
<tr>
<td>Interest/Investment</td>
<td>$(653,695)</td>
<td>$236,854</td>
</tr>
<tr>
<td>In Kind Contributions</td>
<td>$105,762</td>
<td>$82,524</td>
</tr>
<tr>
<td>Other Income</td>
<td>$(2,720)</td>
<td>$54,518</td>
</tr>
<tr>
<td><strong>TOTAL REVENUES</strong></td>
<td><strong>$10,685,409</strong></td>
<td><strong>$7,565,800</strong></td>
</tr>
</tbody>
</table>

**EXPENSES**

<table>
<thead>
<tr>
<th>Description</th>
<th>TOTAL 2022</th>
<th>TOTAL 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Research Grants</td>
<td>$12,272,878</td>
<td>$8,761,340</td>
</tr>
<tr>
<td>Personnel Costs</td>
<td>$2,065,037</td>
<td>$1,837,282</td>
</tr>
<tr>
<td>Travel &amp; Entertainment</td>
<td>$399,336</td>
<td>$49,006</td>
</tr>
<tr>
<td>Other Expenses</td>
<td>$518,951</td>
<td>$540,770</td>
</tr>
<tr>
<td>Meetings &amp; Conferences</td>
<td>$251,723</td>
<td>$31,261</td>
</tr>
<tr>
<td>Professional Fees</td>
<td>$332,379</td>
<td>$176,275</td>
</tr>
<tr>
<td>Occupancy</td>
<td>$115,677</td>
<td>$157,020</td>
</tr>
<tr>
<td><strong>TOTAL EXPENSES</strong></td>
<td><strong>$15,955,981</strong></td>
<td><strong>$11,552,954</strong></td>
</tr>
<tr>
<td><strong>NET INCOME/(LOSS)</strong></td>
<td><strong>($5,270,572)</strong></td>
<td><strong>($3,987,154)</strong></td>
</tr>
</tbody>
</table>

100% of all donations go directly to research—no admin, development, or other fees

DONATE TODAY: give.CureMelanoma.org
DONOR RECOGNITION

A heartfelt thank you to all of our 2022 donors. Your generosity makes our work possible:
give.curemelanoma.org

$1,000,000+
Debra and Leon Black
Anna-Maria and Stephen Kellen Foundation
Denise and Michael Kellen Foundation
The Stewart J. Rahr Foundation

$500,000-$999,999
Bristol-Myers Squibb Company
Paul, Weiss, Rifkind, Wharton & Garrison LLP
Richard and Alison Ressler

$250,000-$499,999
Bank of America Private Bank
Goldman Sachs & Co.
Kirkland & Ellis LLP
Jonathan and Sheryl Sokoloff

$100,000-$249,999
Akin Gump Strauss Hauer & Feld LLP
Lee and Debbi Alpert
Caryl Englebard
Michael and Jacqueline Ferro Family Foundation
Fitch Ratings
HPS Investment Partners, LLC
Iron Park Capital, LP
Latham & Watkins LLP
Ronald and Jo Carole Lauder
L’Oréal Active Cosmetics Division
Merck & Co., Inc.
Mike and Lori Milken
Polka Dot Mama Melanoma Foundation
PricewaterhouseCoopers
Robbins Family Fund of The Bessemer Trust
Jeffrey and Frances Rowbottom
Ian Schuman
Simpson Thacher & Bartlett LLP
The Wayne Stinchcomb Big Orange Foundation
Tara Miller Melanoma Foundation
Veritas Capital Management, Inc.
White & Case LLP

$50,000-$99,999
Allen & Overy
The Alta Vista Fund of the Chicago Community Foundation
Amgen, Inc.
Anonymous
Apollo|MidCap
BioNTech AG
Bloomberg L.P.
BMO Capital Markets
Brownstein, Hyatt, Farber & Schreck
Barry and Joyce Cohen
Davis Polk & Wardwell
Deloitte
Michael and Jacqueline Ferro
Iovance Biotherapeutics
Thomas Lee and Ann Tenenbaum
Nektar Therapeutics
O’Melveny & Myers
Eyal & Marilyn Ofer Family Foundation
Shearman & Sterling LLP
Sidley Austin LLP
UBS Financial Services

$25,000-$49,999
Agenus, Inc.
Alkermes, Inc.
Bank of America Merrill Lynch
Barclays
Brinley Partners LP
Castle Biosciences, Inc.
Checkmate Pharmaceuticals
Citi

The Gay Libertarian Fund
General Atlantic Philanthropic Foundation
Golub Capital
Hellman & Friedman LLC
Instil Bio
Intesa Sanpaolo
J.P. Morgan Chase & Co.
Johnson & Johnson
King & Spalding
The Ronald & Jo Carole Lauder Foundation
Leonard Green & Partners
Gregory and Sharon Maffei
Nancy and Howard Marks
Milbank LLP
MUR Foundation
Morgan, Lewis & Bockius LLP
Morgan Stanley
Natera
Network Financial Printing, Inc.
New Mountain Capital
Pfizer, Inc.
Proskauer Rose LLP
Mary Jo and Brian Rogers
Ropes & Gray LLP
Royal Bank of Canada/RBC Capital Markets
Matthew and Rijalda Savino
Adam Shapiro and Pam Wasserstein
Silver Lake
Sixth Street Partners
Skadden, Arps, Slate, Meagher & Flom LLP
T. Rowe Price
TD Securities
The Brown Foundation Inc. of Houston
The Carlyle Group
Thoma Bravo
TPG/Tarrant Capital
Vista Equity Partners
Weil, Gotshal & Manges LLP
Wells Fargo Bank
James and Vivian Zelter
$10,000-$24,999

M. Mark Albert
American Industrial Partners
Angelo Gordon & Co.
Anonymous
Ares Management LLC
Clare Baillie
BC Partners LLP
Carole Black
Blackstone Credit
Blue Owl Capital
Ward Blum and Ronnie Heyman
BNP Paribas
Boat Racing LLC
Dale Bottoms and John Ciesielka
Debra Bottoms
Brian and Melissa Carney
Centerbridge Partners
Checkmate Pharmaceuticals
Alex Chi
Clayton, Dubilier & Rice LLC
Cleary Gottlieb Steen & Hamilton LLP
Ronald Cohen and Sharon Harel-Cohen
Combined Federal Campaign
Lee Grinberg and Jennifer Corwin
Cravath, Swaine & Moore LLP
Credit Suisse
The Hon. Ivo Daalder and Elisa Harris
Ellen and Gary Davis
Col. Wallace Dawson
Debevoise & Plimpton LLP
DermTech International
Deutsche Bank
Brendan and Eva Dillon
Eisai Inc.
Elsevier Business Intelligence
Fortinbras Enterprises
Scot French
Fried, Frank, Harris, Shriver & Jacobson LLP
Richard and Kathy Fuld
Gabriel Gelman
J. Littleton Glover
Kenneth Griffin
GTCR
Christopher Harland and Ashley Leeds
Haen Polsky Foundation
H.I.G. Capital
HSBC Bank
Immunocore
Jefferies Financial Group
The Ketterer Family Foundation
KKR
Robert Kraft and Dana Blumberg
LSTA
David Ludwig
Macquarie Group
Madison Dearborn Partners
Matthew and Mary Catherine Manin
Christina Minnis
Mitsubishi UFJ Financial Group, Inc.
Mizuho Securities USA, Inc.
MJX Asset Management LLC
Oak Hill Advisors, LP
Oak Hill Capital Management
Eyal and Marilyn Ofer
Jonathan Ofer
Gregory Olafson
Pantheon Ventures (US) LP
PRIME Education
Robert Pulford
Harley and Bob Raiff
Regeneron
The Reiss Family Foundation
Mark Rubenstein
Elliott and Ruth Sigal
Silver Rock Financial
SPOTMYUV
Kevin Sterling
Stone Canyon Industries
Stone Point Capital
Sullivan & Cromwell LLP
Tiger Global Management
Trobman Family Charitable Trust
Wachtell, Lipton, Rosen & Katz
Warburg Pincus LLC
Brad Wechsler and Patty Newburger
Erika Weinberg and Matt Nord
Winston & Strawn
BlackRock
James Bonetti
Brody Family Foundation
Brookfield
Norm and Sunny Brownstein
Capital One Bank
Clarion Capital Partners, LLC
Israel Englander
Michael and Sarah Fenstermacher
Foundation Medicine, Inc.
Gem Star Foundation
GigaGen, Inc.
GoldenTree Asset Management
Lauren Hanrahan
Stratton and Rhonda Heath
William Helman
Holland & Knight
Houlihan Lokey, Inc.
Carl and Gail Icahn
Elizaabeth L. Johnson Fund
Michael Lee
David L. Lieb Foundation
Irina Liner and Marcel van Poecke
Meeting Masters, Inc.
Suzy, Nancy and Carol Minkoff Charitable Fund
Mollie Biggane Melanoma Foundation
Natixis
NeraCare
Obsidian Therapeutics, Inc.
Gregory Olafson
OFS Capital Management
Paul Hastings LLP
PNC Bank
Malcolm Price and Catherine Kuehn Price
Radimmune Therapeutics, Inc.
Riverstone LLC
Rothschild & Co.

$5,000-$9,999

Advent International Corporation
Angelo Gordon & Co.
Anonymous
Ardea Cares
Breanna and Cassidy Battin
Arie and Rebecka Beldegrun

Sir Paul Ruddock and Lady Jill Shaw Ruddock
Secura Bio, Inc.
Seix Investment Advisors LLC
Shenkman Capital Management, Inc.
Siris Capital Group, LLC
James Skelton
Sony Music Entertainment
Beatrice Stern
Stonepeak
Sumitomo Mitsui Banking Corporation
Stephanie Teicher
Todd Goodwin Charitable Trust
Z Capital Group

$1,000-$4,999
The 77 Foundation, Inc.
Christopher Abbate
Dina Acciai and Frank Basile
Andrew Adams
Jeffrey Aleshire
Joanne Ally
Amazon
Anonymous
Apple
Rome and Lisa Arnold
James Austin
Shant Babikian
Brandon and Lida Barniea
Margaret Betzel
Andrew Black
Thomas Bolas
Jamie Brodsky
Vanessa Brown
Kellie Burdick
John and Wendy Burnett
Terri Butler
Todd Carriker
CBRE Group, Inc.
Alan Cheng
Brady Cherneski
Jay and Gretchen Clayton
Maurice and Gayle Cohen
Linda Conely
James Connolly
Conscious Alliance
Scott Cullerton
Jerold Danis
Jennifer Davidson
Brian and Yvonne Day
The Geaton & Joann Decesaris Family Foundation Inc.
Kerry Dolan and Alexander Byers
Max Dow
Craig and Janet Duchossois
Kelly Dybala
Paula Ehrlich
Jacob Elhganayan
Dimitri Evanoff
Susan and Peter Evensen
John Eydenberg
Erik Fiebert
Fidelity Charitable Gift Fund
Craig Fitt
Margaret Flynn
Angela Fontana
Shelley Franco
Thomas Freyman
Rondi and David Frieder
Mrs. Ruth Friedman and Mrs. Beth Ann
Hopkins Fund
Robert Fullerton
James Gardner
Alison Gibraski
Greg Gliner
Mark Goldman
Goldman Sachs Gives
Great Salt Plains Health Center, Inc.
Jeffrey Greenip
JP and Lauren Gutfreund
Cristina Haegg
Cynthia Hartung
Todd and Jamie Hasson
Linda Hinds
Gerry Hogue
Patrick Hunt
Marc Hurlbert
Victor A. Hurlbert
Brett Icahn
Dennis and Betty Jacobson
Karen Karmolinski
Brad and Roberta Karp
Elizabeth Kelly
The list of donors who generously contributed $999 or less in 2022 can be found on the MRA website.
THE PEOPLE OF MRA
THE PEOPLE
OF MRA

Board of Directors

Organizational Affiliations and Titles are included to identify individuals, however, all individuals listed serve in a personal capacity, and not as a representative of the organization to which they are employed.

Debra Black
Co-Founder & Chair, MRA

Leon Black
Co-Founder, MRA

Ben Black
Managing Partner
Fortinbras Enterprises

Lee Alpert
Founder
Lee Alpert & Company

Evan Bayh
Senior Advisor
Apollo Management

Maria Bell
Television Writer
Television Producer

Barry Cohen
President
Elysium Management

Ellen Davis
Principal
Makana Beverages

Amanda Eilian
Partner and Co-Founder
_able Partners

Jason Daniel Federici
Art Director

Jami Gertz
Television and Film Actress
Atlanta Hawks Owner

Daisy Helman
CEO and Founder
Garden Collage

Susan Hess
Vice Chairman
Whitney Museum

Denise Kellen
Patient Advocate
Philanthropist

Michael Klowden
Executive Chairman
Milken Institute Board
Milken Institute

Nancy Marks

Michael Milken
Chairman
Milken Institute

Richard Ressler
Founder & President
Orchard Capital Corporation
and CIM Group

Mary Jo Rogers
Melanoma Patient
Melanoma Advocate

Jeffrey Rowbottom
Managing Director
General Atlantic Credit

Ian Schuman
Global Chair,
Capital Markets Practice
Latham & Watkins

Jonathan W. Simons, MD
Medical Director and
Chief Science Officer
Marcus Foundation

Jonathan Sokoloff
Managing Partner
Leonard Green & Partners, LP

Elizabeth Stanton

Suzanne L. Topalian, MD
Professor, Surgery and Oncology
Johns Hopkins Medicine

Jeff Rowbottom (L) speaks at the 2022 Leveraged Finance Fights Melanoma event with (L to R): Charlotte Arinyan, MD, PhD — Memorial Sloan Kettering Cancer Center, Jedd Wolchok, MD, PhD — Weill Cornell Medical College, Michael Milken — MRA Board of Directors, and Stephanie Kauffman — MRA President & COO

Mary Jo Rogers — MRA Board of Directors, Stephanie Kauffman at MRA Live: Naples, Florida Salon
MRA Team

Marc Hurlbert, PhD  
Chief Executive Officer

Stephanie Kauffman  
President & Chief Operating Officer

Joan Levy, PhD  
Chief Science Officer

Tanisha Jackson, PhD  
Scientific Program Director

Cody Barnett, MPH  
Senior Director of Communications & Patient Engagement

Janine Rauscher  
Associate Director, Development & Information Management

Rachel Fischer, PhD  
Associate Director, Scientific Program & Registry

Renee Orcione  
Digital Engagement & Communications Manager

Kris’tina Ackerman, MIS  
Operations & Grants Administration Coordinator

Laurel Farr, MA  
Development Associate

Melanoma > Exchange

COMMUNITY LEADERS

The Melanoma > Exchange, available at CureMelanoma.org/Community is a vibrant online community led by patients and caregivers with firsthand understanding of melanoma and clinical trials and experts from the MRA staff.

(Pictured below, left to right)

Cheryl Adams  
Jamie Troil Goldfarb  
Keith Tolley  
T.J. Sharpe  
Tracy Callahan

Kristina Baum —  
Melanoma Patient Advocate

The MRA team at the 2023 Leveraged Finance Fights Melanoma event
MRA Scientific Advisory Panel 2022-2023

Organizational Affiliations and Titles are included to identify individuals, however, all individuals listed serve in a personal capacity, and not as a representative of the organization to which they are employed.

Suzanne Topalian, MD — Chair
Professor, Surgery and Oncology
Director, Melanoma Program
Chair for Cancer Immunotherapy
Johns Hopkins Medicine

James Allison, PhD
Regental Professor & Chair, Department of Immunology
Olga Keith Wiess Distinguished University Chair for Cancer Research
Director, Parker Institute for Cancer Immunotherapy
Executive Director, Immunotherapy Platform
Deputy Director, David H. Koch Center for Applied Research of Genitourinary Cancers
The University of Texas, MD Anderson Cancer Center

Boris Bastian, MD, PhD
Professor, Dermatology and Pathology
Gerson and Barbara Bass Bakar Distinguished Professor, Cancer Research
University of California, San Francisco

Gideon Bollag, PhD
Chief Executive Officer
Plexxikon, Inc.

Glenn Dranoff, MD
Global Head of Immuno-Oncology
Novartis Institutes for Biomedical Research

Gregory Friberg, MD
Vice President Medical Affairs ELMAC Region
Amgen

Gina Fusaro, PhD
Vice President, Development Program Lead Oncology Clinical Development
Bristol Myers Squibb

Levi Garraway, MD, PhD
Chief Medical Officer and Executive Vice President
Head of Global Product Development
Roche & Genentech

Allan C. Halpern, MD
Chief, Dermatology Service
Associate Chair, Promotions Advisory Committee, Department of Medicine
Memorial Sloan Kettering Cancer Center

Nageatte Ibrahim, MD
Vice President, Oncology, Global Clinical Development
Merck

Howard Kaufman, MD
Head of Research and Development, Immuneering
Lecturer, Surgery, Harvard Medical School

Jeffrey Legos, PhD
Executive Vice President, Global Head of Oncology Development
Novartis Pharmaceuticals Corporation

Richard Marais, PhD, FMedSci
Director, Cancer Research
Professor, Molecular Oncology
UK Manchester Institute

Grant McArthur, PhD, FRACP
Fellow, Royal Australasian College of Physicians
Executive Director
Victorian Comprehensive Cancer Centre
Inaugural Lorenzo Galli Chair of Melanoma and Skin Cancers
University of Melbourne
Senior Principal Research Fellow
National Health & Medical Research Council Head, Molecular Oncology Laboratory and Cancer Therapeutics Program
Senior Consultant Medical Oncologist, Cancer Medicine
Peter MacCallum Cancer Centre

Ira Mellman, PhD
Vice President, Cancer Immunology
Genentech

Caroline Robert, MD, PhD
Head, Dermatology Unit
Co-Director, Melanoma Research Unit
Professor, Dermatology
Institute Gustave Roussy

Neal Rosen, MD, PhD
Enid A. Haupt Chair in Medical Oncology
Memorial Sloan Kettering Cancer Center

David Solit, MD
Geoffrey Beene Chair
Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

Tara Withington, CAE
Vice President
Executive Director, Inc.
Executive Director Emeritus
Society for Immunotherapy of Cancer
MRA Medical Advisory Panel 2022-2023

Organizational Affiliations and Titles are included to identify individuals, however, all individuals listed serve in a personal capacity, and not as a representative of the organization to which they are employed.

MEDICAL ONCOLOGY

Michael Atkins, MD - Chair
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
Professor, Oncology and Medicine (Hematology/Oncology), Georgetown University Medical Center
Acting Chief, Division of Hematology/Oncology
MedStar Georgetown University Hospital

Paul Chapman, MD
Attending Physician, Melanoma and Immunotherapeutics Service
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center

Keith Flaherty, MD
Professor, Medicine
Harvard Medical School
Co-Leader, Developmental Therapeutics Dana-Farber / Harvard Cancer Center
Director, Henri and Belinda Termeer Center for Targeted Therapies, Cancer Center
Director, Clinical Research, Cancer Center
Massachusetts General Hospital

Thomas Gajewski, MD, PhD
AbbVie Foundation Professor of Pathology
Professor, Ben May Department of Cancer Research
Professor, Medicine
University of Chicago

F. Stephen Hodi, MD
Professor, Medicine, Harvard Medical School
Sharon Crowley Martin Chair, Melanoma
Director, Melanoma Center
Director, Center for Immuno-Oncology
Dana-Farber Cancer Institute

Siwen Hu-Lieskovan, MD, PhD
Director, Solid Tumor Immunotherapy
Assistant Professor, Medicine
University of Utah, Huntsman Cancer Institute

Patrick Hwu, MD
President and CEO
Moffitt Cancer Center

Kim Margolin, MD, FACP, FASCO
Medical Director, Melanoma Program
Saint John's Cancer Institute, Saint John's Health Center
Professor, Dept of Medicine, Division of Oncology
University of Washington, Fred Hutchinson Cancer Research Center

Antoni Ribas, MD, PhD
Professor, Medicine
Professor, Surgery
Professor, Molecular and Medical Pharmacology
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
Chair, Melanoma Committee, SWOG
University of California, Los Angeles

Hussein Tawbi, MD, PhD
Director, Personalized Cancer Therapy
Deputy Chair, Melanoma Medical Oncology
Professor, Division of Cancer Medicine
University of Texas MD Anderson Cancer Center

Jeffrey S. Weber, MD, PhD
Deputy Director, Perlmutter Cancer Center
Co-Director, Melanoma Research Program
Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine
NYU Grossman School of Medicine

Jedd Wolchok, MD, PhD
Professor of Medicine
Meyer Director, Sandra and Edward Meyer Cancer Center
Weill Cornell Medical College

SURGICAL ONCOLOGY

Charlotte Ariyan, MD, PhD
Carol Bassok Lowenstein Chair
Associate Attending, Gastric & Mixed Tumor Service
Surgeon, Surgical Oncology
Memorial Sloan Kettering Cancer Center

Jeffrey Gershenwald, MD
Professor, Surgical Oncology
Professor, Cancer Biology
The University of Texas MD Anderson Cancer Center

Suzanne Topalian, MD
Professor, Surgery and Oncology
Director, Melanoma Program
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
Johns Hopkins Medicine
DERMATOLOGY

David Fisher, MD, PhD
Chief, Dermatology Service
Director, Melanoma Program, MGH Cancer Center
Director, Cutaneous Biology Research Center
Massachusetts General Hospital

Sancy Leachman, MD, PhD
Chair and Professor, Dermatology
Oregon Health & Science University
Director, Melanoma Research Program
Knight Cancer Institute

Roger Lo, MD, PhD
Director, Melanoma Clinic in Dermatology
Director, Dermatology STAR Residency Program
Professor, Medicine
Associate Chief and Professor, Dermatology
Professor, Molecular & Medical Pharmacology
University of California, Los Angeles, David Geffen School of Medicine

David Polsky, MD, PhD
Alfred W. Kopf, MD Professor of Dermatologic Oncology,
Ronald O. Perelman Department of Dermatology
Professor, Department of Pathology
Vice Chair, Research, Ronald O. Perelman Department of Dermatology
Director, Pigmented Lesion Service
NYU Grossman School of Medicine

Susan Swetter, MD
Professor, Dermatology
Director, Pigmented Lesion & Melanoma Program
Physician Leader, Cancer Care Program in Cutaneous Oncology
Stanford University Medical Center & Cancer Institute

Debra Black — MRA Board Chair and Co-founder & Jonathan Simons, MD — MRA Board of Directors and Marcus Foundation
Organizational Affiliations and Titles are included to identify individuals, however, all individuals listed serve in a personal capacity, and not as a representative of the organization to which they are employed.

**Joshua Arbesman, MD**  
Assistant Professor, Department of Dermatology  
Assistant Professor, Department of Medicine  
Member, Cancer Genomics and Epigenomics Program  
Case Western Reserve University

**Mark Denis P. Davis, MD**  
Consultant, Department of Dermatology  
Chair, Department of Dermatology  
Professor of Dermatology  
Mayo Clinic

**Richard D. Granstein, MD**  
George W. Hambrick, Jr. Professor of Dermatology  
Chairman, Department of Dermatology  
Weill Cornell Medicine

**Daisy Helman (Co-Chair)**  
CEO and Founder  
Garden Collage

**Allan C. Halpern, MD**  
Chief, Dermatology Service  
Associate Chair, Promotions Advisory Committee, Department of Medicine  
Memorial Sloan Kettering Cancer Center

**Denise Kellen (Co-Chair)**  
Patient Advocate  
Philanthropist

**Alexander Meves, MD, MBA**  
Consultant, Dept of Dermatology, Dept of Biochemistry and Molecular Biology  
Associate Professor, Dermatology  
Mayo Clinic

**David Polsky, MD, PhD**  
Alfred W. Kopf, MD Professor of Dermatologic Oncology,  
Ronald O. Perelman Department of Dermatology  
Professor, Department of Pathology  
Vice Chair, Research, Ronald O. Perelman Department of Dermatology  
Director, Pigmented Lesion Service  
NYU Grossman School of Medicine

**Susan Swetter, MD**  
Professor, Dermatology  
Director, Pigmented Lesion & Melanoma Program  
Physician Leader, Cancer Care Program in Cutaneous Oncology  
Stanford University Medical Center & Cancer Institute

**Maria Wei, MD, PhD — University of California San Francisco**
Grant Review Committee
2022-2023

Organizational Affiliations and Titles are included to identify individuals, however, all individuals listed serve in a personal capacity, and not as a representative of the organization to which they are employed.

Ana Carrizosa Anderson, PhD — Chair
Associate Professor, Neurology
Harvard Medical School
Associate Scientist, Neurology
Brigham and Women’s Hospital

Andrew Aplin, PhD
Associate Director, Basic Research Program Leader, Cancer Cell Biology & Signaling, NCI-designated Sidney Kimmel Cancer Center
Professor, Department of Cancer Biology
Thomas Jefferson University

Boris Bastian, MD, PhD
Professor, Dermatology and Pathology
Gerson and Barbara Bass Bakar Distinguished Professor, Cancer Research
University of California, San Francisco

Emily Bernstein, PhD
Co-leader of the Cancer Mechanisms Research Program
The Tisch Cancer Institute
Professor, Oncological Sciences
Professor, Dermatology
Icahn School of Medicine at Mount Sinai

Nina Bhardwaj, MD, PhD
Professor of Medicine and Urology
Director of Immunotherapy
Medical Director of the Vaccine and Cell Therapy Laboratory
Co-Director of the Cancer Immunology Program, The Tisch Cancer Institute
Icahn School of Medicine at Mount Sinai

Marcus Bosenberg, MD, PhD
Professor of Dermatology, Pathology, and Immunobiology
Co-Leader, Genetics, Genomics and Epigenetics, Yale Cancer Center
Director, Yale Center for Immuno-Oncology
Director, Yale SPORE in Skin Cancer
Yale School of Medicine

Richard Carvajal, MD
Deputy Physician-in-Chief
Director of Medical Oncology
Northwell Health Cancer Institute
R.J. Zuckerberg Chair in Medical Oncology
Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell

Paul Chapman, MD
Attending Physician, Melanoma and Immunotherapeutics Service
Professor of Medicine, Weill Cornell Medical College
Memorial Sloan Kettering Cancer Center

Keith Flaherty, MD
Professor, Medicine
Harvard Medical School
Co-Leader, Developmental Therapeutics Dana-Farber / Harvard Cancer Center
Director, Henri and Belinda Termeer Center for Targeted Therapies, Cancer Center
Director, Clinical Research, Cancer Center
Massachusetts General Hospital

Thomas Gajewski, MD, PhD
AbbVie Foundation Professor of Pathology
Professor, Ben May Department of Cancer Research
Professor, Medicine, University of Chicago

Jeffrey Gershenwald, MD — Co-Chair
Medical Director, Melanoma and Skin Center
Professor, Department of Surgical Oncology
The University of Texas MD Anderson Cancer Center

Tanja de Gruijl, PhD
Professor, Medical Oncology Laboratory
Professor, Amsterdam Infection and Immunity — Cancer Immunology
Professor, Cancer Center Amsterdam — Cancer Biology and Immunology, Imaging and Biomarkers
Vrije Universiteit, Amsterdam

David Fisher, MD, PhD
Chief, Dermatology Service
Director, Melanoma Program, MGH Cancer Center
Director, Cutaneous Biology Research Center
Massachusetts General Hospital
J. William Harbour, MD
Professor, Ophthalmology, Biochemistry and Molecular Biology
Mark J. Daily Chair, Ophthalmology,
Vice Chairman, Translational Research
Director, Ocular Oncology
Eye Cancer Site Disease Group Leader
Associate Director, Basic Research, Sylvester Comprehensive Cancer Center
Bascom Palmer Eye Institute, University of Miami

Eva M. Hernando-Monge, PhD
Professor, Department of Pathology
New York University Langone Health

Thomas Hornyak, MD, PhD
Chief, Dermatology
Associate Chief of Staff, Research & Development
VA Maryland Health Care System
Associate Professor, Dermatology and Biochemistry and Molecular Biology
University of Maryland School of Medicine

Roger Lo, MD, PhD
Director, Melanoma Clinic in Dermatology
Director, Dermatology STAR Residency Program Professor, Medicine
Associate Chief and Professor, Dermatology Professor, Molecular & Medical Pharmacology
University of California, Los Angeles, David Geffen School of Medicine

David Lombard, MD, PhD
Professor
Department of Pathology & Laboratory Medicine
Co-Leader, Cancer Epigenetics Program
Sylvester Comprehensive Cancer Center
Miller School of Medicine

Michal Lotem, MD
Head, Center for Melanoma and Cancer Immunotherapy, Dept of Oncology
Hadassah Hebrew University Medical Center

Glenn Merlino, PhD
Senior Investigator, Laboratory of Cancer Biology and Genetics
Head, Cancer Modeling Section
Scientific Director for Basic Research, CCR National Cancer Institute

Poulikos Poulikakos, PhD
Associate Professor, Department of Oncological Sciences
Icahn School of Medicine at Mount Sinai
Precision Immunology Institute
The Tisch Cancer Institute

Antoni Ribas, MD, PhD
Professor of Medicine, Surgery, Molecular and Medical Pharmacology
Director, Tumor Immunology Program, Jonsson Comprehensive Cancer Center
Director, Parker Institute for Cancer Immunotherapy Center at UCLA
University of California Los Angeles

Caroline Robert, MD, PhD
Head, Dermatology Unit
Co-Director, Melanoma Research Unit
Professor, Dermatology
Institute Gustave Roussy

Jonathan Simons, MD
Chief Science Officer
Medical Director
The Marcus Foundation

Craig Slingluff, MD
Joseph Helms Farrow Professor, Surgery
Vice Chair, Research, Department of Surgery
Director, UVA Cancer Center Human Immune Therapy Center
Co-Chair, Melanoma Committee of ECOG
The University of Virginia

Marisol Soengas, PhD
Dean for Academic Affairs
Professor
Spanish National Cancer Research Center

David Solit, MD
Geoffrey Beene Chair
Director, Marie-Josée & Henry R. Kravis Center for Molecular Oncology
Memorial Sloan Kettering Cancer Center

Daisy Helman – MRA Board of Directors and Co-Chair of MRA’s Dermatology Council

Susan Swetter, MD
Professor, Dermatology
Director, Pigmented Lesion & Melanoma Program
Physician Leader, Cancer Care Program in Cutaneous Oncology
Stanford University Medical Center & Cancer Institute

Jennifer Wargo, MD, MMSc
Professor, Genomic Medicine
Professor, Surgical Oncology
The University of Texas MD Anderson Cancer Center

Jeffrey S. Weber, MD, PhD
Deputy Director, Perlmutter Cancer Center
Co-Director, Melanoma Research Program
Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine
NYU Grossman School of Medicine

Xu Wu, PhD
Principal Investigator, Cutaneous Biology Research Center, Massachusetts General Hospital
Associate Professor, Dermatology, Harvard Medical School
Affiliate Faculty, Harvard Stem Cell Institute

Kai Wucherpfennig, MD, PhD
Chair, Cancer Immunology and Virology
Director, Center for Cancer Immunotherapy Research
Dana-Farber Cancer Institute
Professor, Neurology, Brigham and Women’s Hospital and Harvard Medical School
Associate Member, Broad Institute of MIT and Harvard

Iwei Yeh, MD, PhD
Associate Professor, Dermatology and Pathology
University of California, San Francisco
RARE Registry Oversight Committee 2022-2023

CO-PRINCIPAL INVESTIGATORS
Joan Levy, PhD
Melanoma Research Alliance
Maryam Asgari, MD, MPH
University of Colorado Anschutz School of Medicine

SCIENTIFIC & PATIENT ADVISORS
Boris Bastian, MD
University of California San Francisco
Trena Brown
Patient Advocate
Elizabeth Buchbinder, MD
Dana-Farber Cancer Institute
Chris Carr
Patient Advocate

Richard Carvajal, MD
Columbia University-New York Presbyterian Hospital
Judith Colin
Patient Advocate
Julie Dewey
Patient Advocate
Rachel Fischer, PhD
Melanoma Research Alliance
Marc Hurlbert, PhD
Melanoma Research Alliance
Patricia Janiak
Patient Advocate
Amy Jardon
Patient Advocate
Jason Luke, MD
University of Pittsburgh Medical Center

David Marx
Patient Advocate
Sapna Patel, MD
The University of Texas MD Anderson Cancer Center
Yevgeniy ‘Eugene’ Semenov, MD, MS
Massachusetts General Hospital
Alex Shoushtari, MD
Memorial Sloan Kettering Cancer Center
Jonathan Swingle
Patient Advocate
Alfonso Waller, MD
Patient Advocate
Eileen Walther
Patient Advocate

J.B. Ward
Patient Advocate
Janet Yannelli
Patient Advocate
Iwei Yeh, MD, PhD
University of California San Francisco

MRA Leadership Council

The Melanoma Research Alliance Leadership Council is a proud community of individuals committed to melanoma research, patient engagement, and advocacy. The Leadership Council advances MRA’s mission in a number of ways including serving as MRA ambassadors, lending access to their networks, sharing their unique expertise, and encouraging others to join in and support MRA.

Leah Adams
Jon Alagem
Trena Brown
Tracy Callahan
Ellie Cohen
Jennifer Corwin
Kerry Dolan

Bill Evans
Hilary Mauro
Brooke McKnight
Kristi Miller
Lauren Miller Parker
George Mueller
Patrick O’Neill

Camille Price
Derrick Queen
Lois Robbins
Stacy Small